Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use

During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer an...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-09, Vol.17 (9), p.1502-1502
Main Authors: Mlakar, Vid, Huezo-Diaz Curtis, Patricia, Satyanarayana Uppugunduri, Chakradhara Rao, Krajinovic, Maja, Ansari, Marc
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Child
cisplatin
Congresses as Topic
cyclophosphamide
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - pharmacokinetics
Enzyme Inhibitors - therapeutic use
Humans
irinotecan
Medical Oncology - methods
methotrexate
pediatrics
Pediatrics - methods
Pharmacogenetics - methods
pharmacogenomics
PharmGKB
Protein Binding
Review
thiopurine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer and harmonization of pharmacogenetic testing from research into clinics, to bring together basic and translational research and to educate health professionals throughout Europe. The objective of this review was to provide the attendees of the meeting as well as the larger scientific community an insight into the compiled evidence regarding current pharmacogenomics knowledge in pediatric oncology. This preliminary evaluation will help steer the committee's work and should give the reader an idea at which stage researchers and clinicians are, in terms of personalizing medicine for children with cancer. From the evidence presented here, future recommendations to achieve this goal will also be suggested.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms17091502